ReviewFrontiers in pharmacology2023
Hepatotoxic mechanism of cantharidin: insights and strategies for therapeutic intervention.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- AI/ML-based computational models for toxicity prediction.Environmental science and pollution research international · 2026Review
- Processing-induced detoxification of toxic Traditional Chinese Medicines: a systematic review of attenuation mechanisms at physical, chemical, and in vivo levels.Chinese medicine · 2026Review
- Ginsenoside RG3 and cantharidin synergistically suppress the progression of hepatocellular carcinoma via targeting the PRMT1-SREBF1 axis-mediated lipid metabolism.Journal of translational medicine · 2026Article
- Uncovering cantharidin's mechanism for cholangiocarcinoma treatment using patient-derived tumor organoids.iScience · 2025Article
- An overview of the research progress on Mylabris: entomology, active ingredients, traditional use, pharmacology, clinical application, pharmacokinetics, toxicity and detoxification strategies.Chinese medicine · 2025Review
- Cantharidin-Loaded Nanomedicine Modified with Amphiphilic Peptides Induce Immunogenic Cell Death to Enhance PD-1 Blockade.ACS applied materials & interfaces · 2025Article
- Recent Advances in the Mechanisms and Applications ofMolecules (Basel, Switzerland) · 2025Review
- A chromosome-level genome assembly of Mylabris sibirica Fischer von Waldheim, 1823 (Coleoptera, Meloidae).Scientific data · 2025Article
- Cantharidin: a double-edged sword in medicine and toxicology.Frontiers in pharmacology · 2025Review
- Essential Oils fromMetabolites · 2024Article
- Glycyrrhetinic acid-modified redox-sensitive polymeric mixed micelles for tumor-specific intracellular delivery of cantharidin.RSC advances · 2024Article
- A Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer.ACS omega · 2024Review
- DDIT4/mTOR signaling pathway mediates cantharidin-induced hepatotoxicity and cellular damage.Frontiers in pharmacology · 2024Article
- Aconitine and its derivatives: bioactivities, structure-activity relationships and preliminary molecular mechanisms.Frontiers in chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cantharidin (CTD), a natural compound derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.